Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP3 | P08254 | 2/20 | 0.36 |
| ▸ | MMP7 | P09237 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2987273 | 0.81 | SLC1A3 (0.45) | MMP2MMP3MMP7MMP1ALDH1A1 | |
| SCHEMBL4798136 | 0.81 | SLC1A3 (0.45) | MMP2MMP3MMP7MMP1ALDH1A1 | |
| SCHEMBL2987274 | 0.81 | SLC1A3 (0.45) | MMP2MMP3MMP7MMP1ALDH1A1 | |
| SCHEMBL9593104 | 0.80 | MMP1 (0.31) | MMP2MMP3MMP7MMP1 | |
| SCHEMBL2997284 | 0.79 | MMP1 (0.35) | MMP2MMP3MMP7MMP1GRIK1 | |
| SCHEMBL8422179 | 0.79 | TSHR (0.39) | MMP2MMP3MMP7MMP1ALDH1A1 | |
| SCHEMBL2997282 | 0.79 | MMP1 (0.35) | MMP2MMP3MMP7MMP1GRIK1 | |
| SCHEMBL8418425 | 0.79 | TSHR (0.39) | MMP2MMP3MMP7MMP1ALDH1A1 | |
| SCHEMBL3355256 | 0.79 | TSHR (0.39) | MMP2MMP3MMP7MMP1ALDH1A1 | |
| SCHEMBL3322985 | 0.79 | GRIK1 (0.35) | MMP2MMP3MMP7MMP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | HAVCR2, HPD, CYP24A1 | MMP2 3339/4885MMP3 3815/4885MMP7 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.